Abstract
Background Obstructive sleep apnea (OSA) is associated with COVID-19 infection. Fewer investigations have assessed OSA as a possible risk for the development of Post-Acute Sequelae of SARS-CoV-2 infection (PASC).
Research Question In a general population, is OSA associated with increased odds of PASC-related symptoms and with an overall definition of PASC?
Study Design Cross-sectional survey of a general population of 24,803 U.S. adults.
Results COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence rates for a wide variety of persistent (> 3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models adjusted for demographic, anthropometric, comorbid medical and socioeconomic factors, OSA was associated with all putative PASC-related symptoms with the highest adjusted odds ratios (aOR) being fever (2.053) and nervous/anxious (1.939) respectively. Elastic net regression identified the 13 of 37 symptoms most strongly associated with COVID-19 infection. Four definitions of PASC were developed using these symptoms either weighted equally or proportionally by their regression coefficients. In all 4 logistic regression models using these definitions, OSA was associated with PASC (range of aORs: 1.934-2.071); this association was mitigated in those with treated OSA. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9%.
Conclusion In a general population sample, OSA is associated with the development of PASC-related symptoms and a global definition of PASC. A PASC definition requiring the presence of 3 or more symptoms may be useful in identifying cases and for future research.
Competing Interest Statement
MDW reported consulting fees from Fred Hutchinson Cancer Center, the National Sleep Foundation, and the University of Pittsburgh. MEC reported personal fees from Vanda Pharmaceuticals Inc., research grants or gifts to Monash University from WHOOP, Inc., Hopelab, Inc., CDC Foundation, and the Centers for Disease Control and Prevention. CAC reported receiving grants and personal fees from Teva Pharma Australia, receiving grants from the National Institute of Occupational Safety and Health R01-OH-011773, personal fees from and equity interest in Vanda Pharmaceuticals Inc, educational and research support from Philips Respironics Inc, an endowed professorship provided to Harvard Medical School from Cephalon, Inc, an institutional gift from Alexandra Drane, and a patent on Actiwatch-2 and Actiwatch-Spectrum devices with royalties paid from Philips Respironics Inc. CACs interests were reviewed and managed by Brigham and Womens Hospital and Partners HealthCare in accordance with their conflict of interest policies. CAC also served as a voluntary board member for the Institute for Experimental Psychiatry Research Foundation, Inc. SMWR reported receiving grants and personal fees from Cooperative Research Centre for Alertness, Safety, and Productivity, receiving grants and institutional consultancy fees from Teva Pharma Australia and institutional consultancy fees from Vanda Pharmaceuticals, Circadian Therapeutics, BHP Billiton, and Herbert Smith Freehills. SFQ has served as a consultant for Best Doctors, Bryte Foundation, Jazz Pharmaceuticals, and Whispersom. RR reports personal fees from SleepCycle AB; Rituals Cosmetics BV; Sonesta Hotels International, LLC; Ouraring Ltd, AdventHealth; and With Deep, LLC. MEH reports grant funding from the Centers for Disease Control and Prevention. No other disclosures were reported.
Funding Statement
This work was supported by the Centers for Disease Control and Prevention. Dr. M. Czeisler was supported by an Australian-American Fulbright Fellowship, with funding from The Kinghorn Foundation. The salary of Drs. Barger, Czeisler, Robbins and Weaver were supported, in part, by NIOSH R01 OH011773 and NHLBI R56 HL151637. Dr. Robbins also was supported in part by NHLBI K01 HL150339
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Monash University Human Research Ethics Committee (Study #24036).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author Approval: All authors have seen and approved the manuscript
Conflicts of Interest: MDW reported consulting fees from Fred Hutchinson Cancer Center, the National Sleep Foundation, and the University of Pittsburgh. MÉC reported personal fees from Vanda Pharmaceuticals Inc., research grants or gifts to Monash University from WHOOP, Inc., Hopelab, Inc., CDC Foundation, and the Centers for Disease Control and Prevention. CAC reported receiving grants and personal fees from Teva Pharma Australia, receiving grants from the National Institute of Occupational Safety and Health R01-OH-011773, personal fees from and equity interest in Vanda Pharmaceuticals Inc, educational and research support from Philips Respironics Inc, an endowed professorship provided to Harvard Medical School from Cephalon, Inc, an institutional gift from Alexandra Drane, and a patent on Actiwatch-2 and Actiwatch-Spectrum devices with royalties paid from Philips Respironics Inc. CAC’s interests were reviewed and managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. CAC also served as a voluntary board member for the Institute for Experimental Psychiatry Research Foundation, Inc. SMWR reported receiving grants and personal fees from Cooperative Research Centre for Alertness, Safety, and Productivity, receiving grants and institutional consultancy fees from Teva Pharma Australia and institutional consultancy fees from Vanda Pharmaceuticals, Circadian Therapeutics, BHP Billiton, and Herbert Smith Freehills.. SFQ has served as a consultant for Best Doctors, Bryte Foundation, Jazz Pharmaceuticals, and Whispersom. RR reports personal fees from SleepCycle AB; Rituals Cosmetics BV; Sonesta Hotels International, LLC; Ouraring Ltd, AdventHealth; and With Deep, LLC. MEH reports grant funding from the Centers for Disease Control and Prevention. No other disclosures were reported.
Preprint Information: Submitted to medrxiv.org
Funding Information: This work was supported by the Centers for Disease Control and Prevention. Dr. M. Czeisler was supported by an Australian-American Fulbright Fellowship, with funding from The Kinghorn Foundation. The salary of Drs. Barger, Czeisler, Robbins and Weaver were supported, in part, by NIOSH R01 OH011773 and NHLBI R56 HL151637. Dr. Robbins also was supported in part by NHLBI K01 HL150339
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
